

Immune defenses of *Xenopus laevis* against *Batrachochytrium dendrobatidis*

Louise A. Rollins-Smith^{1,2}, Jeremy P. Ramsey¹, Laura K. Reinert¹, Douglas C. Woodhams^{1,3}, Lauren J. Livo⁴, Cynthia Carey⁴

¹Department of Microbiology and Immunology, ²Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232 USA, ³Department of Biology, James Madison University, Harrisonburg VA 22807 USA, ⁴Department of Integrative Physiology, University of Colorado, Boulder, CO 80309

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Biology of *B. dendrobatidis*
4. Impact of *B. dendrobatidis* on populations of *X. laevis* (a resistant species) compared to a more sensitive species (*Bufo boreas*)
5. Overview of immune defenses in *X. laevis*.
 - 5.1. Innate immune defenses in *X. laevis*
 - 5.1.1. Complement and lysozyme
 - 5.1.2. Phagocytic cells and natural killer cells
 - 5.1.3. Toll-like receptors
 - 5.1.4. Antimicrobial peptides (AMPs)
 - 5.2. Adaptive immune defenses in *X. laevis*
 - 5.2.1. Lymphoid organs
 - 5.2.2. Major histocompatibility complex (MHC)
 - 5.2.3. Antibody classes
 - 5.2.4. Cytokines and chemokines
 - 5.2.5. T cell-mediated immunity
6. Immune defenses against *B. dendrobatidis*
 - 6.1. Antimicrobial peptide defenses against *B. dendrobatidis*
 - 6.2. Antibody-mediated defenses against *B. dendrobatidis*
 - 6.3. T cell-mediated defenses against *B. dendrobatidis*
7. Can amphibians be immunized to protect them from infection by *B. dendrobatidis*?
8. Future directions for research
 - 8.1. Alternative immunization strategies
 - 8.2. Focus on the skin
9. Perspective and concluding remarks
10. Acknowledgements
11. References

1. ABSTRACT

Amphibian populations are declining at an unprecedented rate worldwide. A number of declines have been linked to a pathogenic skin fungus, *Batrachochytrium dendrobatidis*. Although amphibians have robust immune defenses, many species seem to be very susceptible to infection by this fungus and to development of the lethal disease called chytridiomycosis. One species that is relatively resistant to *B. dendrobatidis* is *Xenopus laevis*. Because *X. laevis* has been used as a model for studies of immunity in amphibians and because it is relatively resistant to chytridiomycosis, it is a good model to examine immune defenses against *B. dendrobatidis*. Although much less is known about immune defenses in *Bufo boreas*, it serves as a second model species because it is very susceptible to *B. dendrobatidis*. Here we review what is known about innate antimicrobial peptide defenses in the skin and the development of immune responses following experimental immunization with heat-killed fungal cells. Development of an immunization protocol in *X. laevis* that induces effective defenses may suggest better strategies for protecting vulnerable species such as *B. boreas*.

2. INTRODUCTION

In 1962 Rachael Carson alerted the world to the dangers of DDT and its impact on bird populations in her carefully researched book, *Silent Spring* (1). At the present time, naturalists are concerned about a different kind of silent spring. Spring in many parts of the world is heralded by the “peeps”, “chirps”, “trills”, and “burps” of many colorful male amphibians calling females to breed. However, beginning in the 1970s, amphibian biologists began to recognize that many familiar species of amphibians were becoming more difficult to find (2-8). In the most recent survey of global amphibian populations published in 2004, approximately 32% of known species were classified as “threatened” (9). This is likely to be an underestimate because there were insufficient data to judge the status of many species (9). Thus, it is clear that many amphibian populations and some entire species are disappearing at an alarming rate (9-11).

There is evidence to support a number of possible causes for amphibian declines including loss of habitat (12, 13, rev in 14), climate change (15-19), increased ultraviolet

Xenopus immune defenses against *B. Dendrobatidis*

(UV-B) radiation (20-24), introduced species (8, 25-29), and toxic environmental chemicals (30-32). However, accumulating evidence suggests that recent declines in amphibian populations in western North America, Central America, South America, Australia, Europe, and Africa have been caused by a chytrid fungus, *Batrachochytrium dendrobatidis* (2, 33-40, rev in 41-44). *B. dendrobatidis* infects the skin and leads to rapid death in highly sensitive species. Here we review what is known about the immune defenses of two model amphibians, *Xenopus laevis* and *Bufo boreas*, against *B. dendrobatidis* and examine what this information can tell us about the possible protective defenses in *X. laevis* and impaired defenses in the more susceptible species, *B. boreas*.

3. BIOLOGY OF *B. DENDROBATIDIS*

B. dendrobatidis is a member of the phylum *Chytridiomycota*, and this phylum occupies a basal position in the kingdom Fungi (45-47). This phylum is characterized by the production of motile zoospores, each propelled by a single flagellum. There are approximately 1000 described species in the phylum *Chytridiomycota*, but only *B. dendrobatidis* is pathogenic to a vertebrate host (45-47). The fungus infects cells of the *stratum granulosum* and *stratum corneum* of the epidermis (33-35, 48). Zoospores appear to attach to skin cells and enter the deeper viable cells of the *stratum granulosum*. The zoospores develop into zoosporangia as these cells move outward and become cornified. Thus, when the dying cornified cells are nearest the exterior of the frog, the mature zoosporangium opens and new zoospores are discharged to the surface of the skin (48). The mechanism by which the fungus causes death of frogs is not well understood. One hypothesis is that *B. dendrobatidis* produces a toxic product (33, 35). An alternative hypothesis that is gaining support is that the general disturbance of the skin resulting from *B. dendrobatidis* infection interferes with the transport of essential ions or water that are needed for life (33,35). A recent study suggests that electrolyte depletion due to disruption of normal epidermal function is correlated with disease severity and death in green tree frogs (*Litoria caerulea*) (49).

4. IMPACT OF *B. DENDROBATIDIS* ON POPULATIONS OF *X. LAEVIS* (A RESISTANT SPECIES) COMPARED TO A MORE SENSITIVE SPECIES (*BUFO BOREAS*)

Archived specimens of *X. laevis* and related species *X. muelleri* and *X. gilli*, collected in the period 1879-1999 and preserved at South African institutions, were examined for the presence of *B. dendrobatidis* by examination of histological sections from the webbing of one hind foot. The overall prevalence of chytridiomycosis among 697 specimens examined was 2.7%, and it was unchanged over time after 1940 (50). *Xenopus* collected in the field do not show signs of illness, and there are no reports of population declines (50) or clinically apparent chytridiomycosis in captive populations of *X. laevis* (51). Thus, populations of *Xenopus* appear to persist with mild

infections that are not debilitating. Experimental infection studies have also shown that this species does not develop disease even when infected with a high number of viable zoospores (52). This contrasts with the related species, *Xenopus tropicalis*, which is thought to be more susceptible to chytridiomycosis (51).

In contrast to *Xenopus*, *B. boreas* is very susceptible to development of chytridiomycosis following exposure to *B. dendrobatidis* in the laboratory or in nature. Boreal toads are long-lived amphibians that inhabit montane habitats in the western USA. This species suffered severe population declines in the southeastern part of its range in the late 1970s to early 1980s that are now suspected to be due to *B. dendrobatidis* (5, 37). *B. dendrobatidis* has been associated with population die-offs in Colorado (53), and the species is designated “endangered” in Colorado and New Mexico. Experimental exposure to as few as 10^4 zoospores for 1 day results in 100% mortality (37).

5. OVERVIEW OF IMMUNE DEFENSES IN *X. LAEVIS*

Because *X. laevis* has been used as a model for studies of amphibian immunity since the 1960s, much is known about immune defenses in this species. No other species of amphibian has been studied in this much detail. Like other vertebrates, *Xenopus* has a set of innate immune defenses that can be mobilized to defend against pathogens without prior exposure. Although innate defenses include recognition of pathogen-associated molecular patterns (PAMPS) that bind to toll-like receptors (TLRs), these defenses are generally not as specific as antibody-mediated and cell-mediated immune responses. However, they do provide an effective first barrier to infection. If infection is not prevented by innate defenses, *Xenopus* can mobilize adaptive antibody and cell-mediated defenses. Both innate defenses and adaptive defenses will be reviewed briefly, and then we will describe what is known about specific defenses against *B. dendrobatidis*.

5.1. Innate immune defenses in *X. laevis*

Innate immune defenses in amphibians include complement, phagocytic cells (macrophages, neutrophils, and natural killer (NK) cells), and production of lysozyme and antimicrobial peptides (AMPs) in the mucous covering the skin. In addition to these known innate mechanisms, it is likely that antigen presenting cells (dendritic cells, Langerhans cells, macrophages, and keratinocytes) in the skin can recognize PAMPS that bind to TLRs to activate both innate and adaptive immune system mediators.

5.1.1. Complement and lysozyme

Like all other vertebrates, *Xenopus* has a very effective complement system that can directly kill pathogens by activation of the alternative pathway of complement and formation of the membrane attack complex. Antibodies bound to pathogens can also activate complement via the classical pathway. Although not all of the individual protein components have been isolated and characterized, it is clear that all of the genes for the

Xenopus* immune defenses against *B. Dendrobatidis

complement components are present (54-63, rev in 64). Another innate mechanism that may be important for protection against invasive bacteria is production of lysozyme in the mucus. Lysozyme belongs to a well-characterized family of enzymes that cleave the bond between N-acetylmuramic acid and N-acetylglucosamine in the peptidoglycan layer of bacterial cell walls. A recent study of the antimicrobial activity of skin secretions of the Chinese toad *Bufo andrewsi* revealed a member of the lysozyme family. The DNA encoding the toad lysozyme had significant homology with that of lysozyme from *X. laevis*, chicken, and turtle (65). Although the gene for lysozyme was identified from *X. laevis* (66), the protein has not been isolated and characterized. Whether or not *B. boreas* may secrete lysozyme in the skin is not yet known. An extract of skin from *Rana pipiens* was previously shown to have an acid-stable protein with lysozyme-like characteristics (67). Thus, lysozyme may be an important bacterial defense mechanism in the mucus of many amphibians.

5.1.2. Phagocytic cells and natural killer (NK) cells

Amphibian skin is also protected by phagocytic cells that can clear microorganisms that penetrate the epithelial layer. Major histocompatibility complex (MHC) class II positive cells, some with dendritic morphology, have been reported in the skin of *X. laevis* and *Rana pipiens* (68-71). Natural killer cells have been characterized in *Xenopus laevis*. They have the potential to provide an immediate cytotoxic response against virus-infected or tumor targets (72-75). Whether they may play a role in recognition and destruction of *B. dendrobatidis*-infected skin cells is unknown.

5.1.3. Toll-like receptors (TLR)

Toll-like receptor (TLR) family proteins recognize conserved patterns expressed by microbes including bacteria, viruses, protozoa, and fungi (rev in 76-78). The molecules recognized include lipoproteins, lipopeptides, lipopolysaccharide, flagellin, and nucleic acids (78). Recognition of the conserved pathogen patterns in mammals activates signaling pathways in antigen presenting cells such as dendritic cells and macrophages that result in production of cytokines, chemokines, interferons and other mediators that contribute to innate defenses as well as activate the adaptive defenses (78). Although the role of TLRs in amphibians has not been studied, a search of the *Xenopus tropicalis* genome has revealed approximately 20 TLR genes with strong homology to those of other vertebrate species that were expressed in a number of tissues including skin (79,80). These include homologs for TLR 2, 3, 4, 5, 6, 7, 8 and 9 which are involved in antifungal responses in mammals (81, rev in 82). Thus, it is likely that TLRs play important roles in amphibian immune defense against a fungus.

5.1.4. Antimicrobial peptides (AMPs)

Early histological studies identified mucous glands and granular glands (also called poison or serous glands) in the dermal layer of amphibian skin (83-86). The mucous glands produce a material rich in mucopolysaccharides that keeps the skin moist (87-89).

Granular glands produce a diverse array of bioactive peptides including neuropeptides and AMPs that are thought to play a role in defense against vertebrate predators as well as microbes (rev in 90-97). Both mucous and granular glands are composed of a syncytium of epithelial cells surrounding a secretory compartment (86,98). In granular glands, the center of the gland is filled with granules packed with active peptides (99). Granular glands are surrounded by a layer of myoepithelial cells with sympathetic axons terminating between the contractile elements (85). The myoepithelial cells possess α -adrenoreceptors, and epinephrine or norepinephrine (NE) induce contraction and release of granular contents by a holocrine mechanism (98,100,101). Holocrine secretion involves loss of most of the contents of the gland; however, the multiple nuclei of the syncytial gland remain, and a new gland regenerates from remaining epithelial cells (102,103). Depending on the species, granular glands can be found all over the body with the largest ones in the dorsolateral skin (dermal plicae) and behind the eyes (paratoid glands) (83-85,102,103).

An extensive literature characterizes the amino acid sequences and activity of a large number of amphibian AMPs ranging in size from 10-50 amino acids. They are active against gram positive and gram negative bacteria, fungi, protozoa, and viruses (rev in 90-97). Although families of peptides are shared by related species, there is virtually no overlap in the individual peptides from one species to another (96). There is no consensus amino acid sequence associated with biological activity, but the peptides are usually cationic, relatively hydrophobic, and have the ability to form an amphipathic α -helix in a membrane-mimetic environment (104). This structure provides them with an ability to disturb biological membranes, and this seems to be the main mechanism of killing of their targets (rev in 92-97).

5.2. Adaptive immune defenses in *X. laevis*

Because *X. laevis* has long been used as a model for studies of the amphibian immune system, we have a very good understanding of the tissues, cells, and molecules that contribute to an effective immune response in this species. In the following paragraphs, we will briefly review what is known about adaptive immune defenses in *Xenopus*. Much less is known about the adaptive immune responses of other anuran amphibians. Very few studies have examined immune responses of species within the genus *Bufo*. However, some basic studies of immune responses in marine toads (*Bufo marinus*) were published in the 1960s and 1970s. Toads responded to particulate antigens (bacteriophage, flagella from *Salmonella adelaide*) by production of IgM and IgG-like antibodies (IgY). The spleen and kidney were identified as major antibody forming organs (105-108). Thus, most comparative immunologists would assume that the adaptive immune responses of toads (genus *Bufo*) would be very similar to those responses described in greater detail for *X. laevis*.

5.2.1. Lymphoid organs

In *Xenopus*, the thymus is the site of development of T lymphocytes. Thymectomy early in life impairs

Xenopus immune defenses against *B. Dendrobatidis*

allograft rejection (109-111), mixed lymphocyte responses, responses to T cell mitogens but not B cell mitogens, and development of lymphocytes with rearranged T cell receptor genes (75,112,113). In adult *Xenopus*, the spleen and liver are the sites of development of B cells and other hematopoietic cells (114). Bone marrow is the site of development of granulocytes (predominantly neutrophils) but not lymphocytes (114). The spleen is the major secondary lymphoid organ where antigens from the blood, peritoneum, and tissue fluids are degraded and come into contact with T and B cells for development of an immune response. *Xenopus* and all other amphibians lack organized lymph nodes (115).

5.2.2. Major histocompatibility complex (MHC)

The major histocompatibility complex (MHC) of *Xenopus* has been characterized in detail (rev in 116-118). It consists of a well-defined class I region that encodes molecules that present peptides to and interact with CD8⁺ T cells (119) and includes other genes that encode proteasome components PSMB8 (LMP7) (120), PSMB9 (LMP2) (121), and the peptide transporters TAP1 (122) and TAP2 (123). Adjacent to the class I genes are the class II genes encoding molecules that present peptides to helper T cells (124,125). Class III genes encode the complement components C4 and factor B and heat shock protein 70 (HSP70) (58-60,126,127). The availability of the *Xenopus tropicalis* genome has provided a new tool to search for additional MHC genes in *Xenopus*. Using this method, approximately 110 genes with significant similarity to MHC genes in other databases were recently identified including class II DM genes (128). Thus, the MHC with its many components needed for regulation of adaptive immune responses is ancient and fully functional in amphibians.

5.2.3. Antibody classes

There are three isotypes of immunoglobulin heavy chain genes in *Xenopus* (rev in 129). They are IgM (130-132), IgY (133,134), and IgX (135,136). Polymeric IgM is the first to develop in ontogeny (137) and is the predominant antibody that develops soon after experimental immunization of tadpoles and adults (129). Slightly later, the low molecular weight (IgG-like) isotype designated IgY develops (129). IgY responses are T cell-dependent (138) and reflect class switch recombination events (139). IgX is a third class of polymeric immunoglobulins found in the gut and may be important in defense of the digestive tract analogous to the function of IgA in mammals (135,136). Recently, the gene for IgD (homologous to IgW in fish) was identified (140).

5.2.4. Cytokines and chemokines

Cytokines that serve to enhance communication between subsets of leukocytes are less well-characterized in *Xenopus* than in mammals or other vertebrate groups. However, a number of cytokines have been identified including interleukin-1 β (141,142), an interleukin-2 like cytokine (143,144), and TGF- β (transforming growth factor-beta) (145). Five genes for type I interferon were identified in a recent search of the *Xenopus tropicalis* genome (146). Recent studies also reveal several

chemokines in *Xenopus*. Stromal cell-derived factor 1 (xSDF-1) shares 64-66% homology with human CXCL12 (147, rev in 148). Expressed sequence tags suggest molecules with homology to CXCL8 and CCL5 of mammals (rev in 148).

5.2.5. T Cell-mediated immunity

Early thymectomy studies demonstrated the involvement of T cells in skin graft rejection (109-111), mixed lymphocyte reactions, and *in vitro* responses to classical T cell mitogens phytohemagglutinin (PHA) and concanavalin A (Con A) (112,113). Skin allograft rejection mediated by T cells is a classical measure of cellular immunity in amphibians. It is dependent on recognition of major histocompatibility complex (MHC) or minor histocompatibility antigens (149-155 rev in 156). It is characterized by classical first- and second-set kinetics and is dependent on the incubation temperature of the hosts (156). The development of genetically identical strains of *Xenopus* (laevis-gilli hybrid strains) (157) permitted studies to demonstrate that both cytotoxic and helper T cell responses are MHC-restricted (158-160). Monoclonal reagents to recognize the CD8 subset of lymphocytes have been developed (161), and the role of CD8 cells in allograft rejection and immune responses to viral infection have been described (163, 164).

In mammalian species, the majority of circulating lymphocytes express T cell receptors (TCRs) generated by the products of TCR- α and - β genes. In contrast, T lymphocytes that home to the skin and mucosal epithelia express TCRs composed of γ/δ heterodimers. *Xenopus* TCR genes of α/β and γ/δ types have been described (165-167). Little is known about the distribution of α/β and γ/δ subsets of lymphocytes in *Xenopus*; however, reagents that are directed to conserved regions of γ/δ TCRs were able to stain a set of lymphocytes in *Xenopus* skin, suggesting that this unique subset is present there (71). In mammals, this subset of cells is thought to recognize protein antigens in an MHC-independent manner and may serve to eliminate "stressed," metabolically compromised, or transformed epithelial cells. In so doing, they promote wound healing in the skin. Whether they play a role in protection of the skin of *Xenopus* is not yet known.

6. IMMUNE DEFENSES AGAINST *B. DENDROBATIDIS*

6.1. Antimicrobial peptide defenses against *B. dendrobatidis*

Xenopus laevis secretes milky white mucus when alarmed, and this species was one of the first for which antimicrobial peptides in skin secretions were described. A number of antimicrobial peptides from this species have been isolated and characterized. They include magainin I and magainin II (168), PGLa (peptide with amino terminal glycine and carboxyl terminal leucinamide) (169), LPF (levitide precursor fragment) (170), XPF (xenopsin precursor fragment) (170,171), and several CPF (caerulein precursor fragment) family members (170,172,173). Matrix-assisted laser desorption ionization (MALDI) time-

Table 1. Serum antibodies (IgM and IgY) binding to *B. dendrobatidis* by ELISA

Treatment	IgM (O.D. ₄₅₀)	IgY (O.D. ₄₅₀)	Number of Frogs
Controls (APBS) ¹	101.2 ± 4.5	7.2 ± 0.6	10
<i>Bd</i> -Immunized ¹	147.7 ± 7.0 ²	169.6 ± 22.8 ²	10

¹Serum collected at day 14 after final injection and diluted 1/100. ²Significantly greater than control values by a one-tailed Student's *t* test; *p*-value ≤ 0.0005.

of-flight (TOF) mass spectrometry (MS) can separate complex mixtures of proteins and peptides based on their known masses. By MALDI-TOF MS it is possible to identify the known AMPs (174). The broad peak of hydrophobic peptides between mass 2600 and 2700 include a number of CPF family members with likely AMP activity, although not all of them have been tested (170,172). Our laboratory has demonstrated antimicrobial activity for three of the purified peptides against *B. dendrobatidis*. The most effective was CPF with a minimal inhibitory concentration (MIC) of 50 μM (175). The MIC for PGLa was 100 μM (175) and for magainin II was 200 μM (L. Rollins-Smith, unpublished data). Two of the peptides (magainin II and PGLa) can act synergistically to inhibit growth of bacteria and *B. dendrobatidis* (175,176). Injection of increasing concentrations of norepinephrine induces the secretion of skin peptides in a dose-dependent fashion (177), and we have observed that a total peptide concentration of 400-1000 μg/ml of enriched hydrophobic peptides effectively inhibits growth of *B. dendrobatidis in vitro* (L. Rollins-Smith, unpublished). To determine the approximate concentration of antimicrobial peptides in the skin mucus of *Xenopus* and other species, we bathed frogs in collection buffer, passed the peptides over a C-18 seppak cartridge to collect the hydrophobic peptides, quantified the peptides by a micro-BCA assay, and determined the total quantity of recovered peptides per gram of frog weight. The standard peptide used for quantification was a nine amino acid peptide found in the skin secretions of many amphibians (bradykinin). We express peptide concentrations as μg equivalents/ml based on the bradykinin standard. If we assume that the mucus layer is 500 μm thick, then the volume of mucus covering one cm² of skin would be 50 μl. The surface area of the skin can be estimated based on the weight in grams (178). Therefore, we are able to quantify the total hydrophobic peptides recovered in the mucus in μg equivalents/ml. For resting frogs (*Xenopus laevis*), the amount recovered is about 126 μg equivalents /ml (L. Rollins-Smith and D. Woodhams, unpublished data). This amount would have little effect on the viability of zoospores that encyst on the skin. However, if *X. laevis* are chased in the water to mimic the effort to escape a predator, the amount of recoverable peptides increases to about 326 μg equivalents/ml. This is in the range of concentrations that would be inhibitory for growth of the fungus (L. Rollins-Smith and D. Woodhams, unpublished data).

In contrast to the expression of a number of effective antimicrobial peptides in the skin secretions of *X. laevis*, *B. boreas* skin secretions appear to contain no conventional antimicrobial peptides. However, there appear to be hydrophobic molecules in the mass range of

about 700 to 750 that can inhibit *B. dendrobatidis in vitro* (174).

6.2. Antibody-mediated defenses against *B. dendrobatidis*

This section summarizes preliminary studies from our laboratory that will be published in greater detail when they are more complete. To investigate whether *X. laevis* could develop an effective immune response against *B. dendrobatidis*, we immunized outbred adults (N= 37) obtained from commercial suppliers with heat-killed *B. dendrobatidis* cells (a mixture of zoospores and mature cells) via the intraperitoneal route. Controls (N= 37) received amphibian phosphate buffered saline (APBS) alone. Blood was drawn by cardiac puncture from 7-10 frogs at one to four weeks after the final immunization (each animal was bled once after immunization), and IgM and IgY antibodies that bind *B. dendrobatidis* cells fixed to a microtiter plate were quantified by ELISA. Immunization resulted in the development of a high-titer antibody response to *B. dendrobatidis* by day 14 that exceeded non-specific binding observed with serum from control frogs (Table 1). Results are shown for serum diluted at 1/100 for animals bled at day 14. The IgY response of *Bd*-immunized frogs was significantly greater than that of controls at all days tested. However, the IgM response was significantly increased only at day 14. These results show that it is possible to generate an antibody response to *Bd* that exceeds non-specific binding in the control frogs. The IgY antibody titers ranged from 1/800 to 1/6400 at day 14 (N = 10; data not shown).

6.3. T Cell-mediated defenses against *B. dendrobatidis*

It is likely that effective immune responses to *B. dendrobatidis* will involve T cell-mediated responses (138,158, 179-183; see below). To begin to investigate T-cell mediated defenses against *B. dendrobatidis*, adult outbred *Xenopus* from our laboratory colony were immunized with heat-killed *B. dendrobatidis* via the dorsal lymph sac at days 0 and 14. Controls were injected with APBS. At day 28, they were given a final injection of the same number of killed *B. dendrobatidis* cells or APBS via the intraperitoneal route in an effort to induce antigen reactive cells to move into the spleen. At day 33, the frogs were sacrificed and spleen cells cultured with phytohemagglutinin (PHA) as a general stimulator of T cells or with freshly killed *B. dendrobatidis* cells. Spleen cells from one of seven *B. dendrobatidis*-immunized frogs showed significant proliferation against *B. dendrobatidis* as well as PHA. The stimulation index against *B. dendrobatidis* was 5.0. The other six responded significantly to PHA but not *B. dendrobatidis*. The stimulation indices against PHA for all seven *B. dendrobatidis*-immunized frogs ranged from 11.9 to 92.8 indicating that T cells from all of the frogs were competent to respond to a T cell target (Table 2). At the same time, splenocytes from three of six APBS-injected control frogs demonstrated significant proliferation in response to freshly killed *B. dendrobatidis* as well as PHA. All six responded significantly to PHA (stimulation indices ranged from 11.6 to 100.4). The stimulation indices against *B. dendrobatidis* were 3.0, 6.2, and 15.9 (Table 2). These proliferation

Table 2. Spleen cell proliferation following immunization with *B. dendrobatidis*

Identifier	CPM ¹ Cells Only	CPM Cells + PHA ²	S.I. ³ PHA	CPM Cells Only	CPM Cells vs. Bd	S.I. ³ Bd
APBS1 ⁴	70 ± 8	4613 ± 264 ⁵	65.9	139 ± 34	190 ± 45	1.4
APBS 2	440 ± 32	5110 ± 149 ⁵	11.6	356 ± 164	2217 ± 184 ⁵	6.2
APBS 3	442 ± 64	29096 ± 377 ⁵	65.8	183 ± 48	2906 ± 558 ⁶	15.9
APBS 4	262 ± 100	7223 ± 1634 ⁶	27.6	1986 ± 548	1289 ± 211	0.6
APBS 5	154 ± 22	5425 ± 660 ⁵	35.2	113 ± 13	342 ± 82 ⁷	3.0
APBS 6	104 ± 18	10456 ± 805 ⁵	100.5	287 ± 108	331 ± 84	1.1
Bd 1 ⁸	86 ± 5	3490 ± 114 ⁵	40.6	70 ± 10	88 ± 12	1.3
Bd 2	756 ± 144	9030 ± 257 ⁵	11.9	1742 ± 456	1947 ± 204	1.1
Bd 3	464 ± 30	33089 ± 895 ⁵	71.3	447 ± 263	2218 ± 536 ⁷	5.0
Bd 4	76 ± 5	7028 ± 249 ⁵	92.5	60 ± 11	50 ± 12	0.8
Bd 5	76 ± 6	5118 ± 513 ⁵	67.3	33 ± 2	48 ± 7	1.4
Bd 6	83 ± 15	5105 ± 1017 ⁶	61.5	80 ± 18	45 ± 8	0.6
Bd 7	704 ± 173	8545 ± 980 ⁵	12.1	2456 ± 536	1338 ± 500	0.5

Abbreviations: ¹ CPM, Counts per minute. ²PHA, Phytohemagglutinin. ³ S. I., Stimulation index = stimulated counts divided by background counts. ⁴APBS control frogs were injected with amphibian phosphate buffered saline at days 0, 14, and 28. Cells were harvested at day 33. ⁵Significantly greater than CPM of cells only, $p \leq 0.0005$. ⁶Significantly greater than CPM of cells only, $p \leq 0.005$. ⁷Significantly greater than CPM of cells only, $p \leq 0.025$. ⁸Bd frogs were immunized with heat-killed *B. dendrobatidis* at days 0, 14, and 28. Cells were harvested at day 33. Cells cultured with PHA were harvested at day 3. Cells cultured with *B. dendrobatidis* were harvested at day 5.

Table 3. Survival of immunized or control *B. boreas* following exposure to infectious *Bd*

Treatment	Number of Toads	Percent Survival Day 35
Controls ¹ not exposed to <i>Bd</i>	42	100
Not injected, <i>Bd</i> exposed	14	0
APBS injected, <i>Bd</i> exposed	14	0
Bd immunized, <i>Bd</i> exposed	15	0

¹Controls consisted of 14 APBS-injected toads, 14 *Bd*-immunized toads, and 14 toads that were not manipulated. None of these controls were exposed to *B. dendrobatidis*. All other toads were exposed to a lethal dose of *B. dendrobatidis* (10^6 zoospores).

responses in non-immunized frogs may suggest that the control frogs have been exposed to *B. dendrobatidis* or related pathogens, and their splenocytes can respond significantly *in vitro*. We did not determine whether the test animals were infected with *B. dendrobatidis*. The relatively weak proliferation responses to *B. dendrobatidis* following immunization may suggest that *B. dendrobatidis* is capable of inhibiting development of a protective response. Further studies are underway to evaluate the cell-mediated immune responses to this pathogen.

7. CAN AMPHIBIANS BE IMMUNIZED TO PROTECT THEM FROM INFECTION BY *B. DENDROBATIDIS*?

Based on our preliminary results demonstrating the development of high-titer antibodies to *B. dendrobatidis* in *Xenopus*, we initiated experiments to determine whether the boreal toad (*Bufo boreas*) could be immunized and protected from experimental *B. dendrobatidis* infection. The Carey laboratory obtained young boreal toads that had been raised in a *B. dendrobatidis*-free hatchery by the Colorado Division of Wildlife, and the animals were immunized in our facility according to a similar immunization protocol that had resulted in high-titer antibody responses in *Xenopus*. After the final immunization, immunized toads, APBS injected control toads, and a third group of uninjected toads were returned to the Carey laboratory for exposure to *B. dendrobatidis*. Each group was divided, and half of the animals were exposed to 10^6 zoospores (37) while the remaining frogs were not exposed to the pathogen. In spite of our efforts to

immunize them, toads injected with the heat-killed pathogen and exposed to live zoospores did not survive better than APBS-injected or uninjected controls that were exposed to *B. dendrobatidis*. In contrast, all toads that were maintained free of exposure to *B. dendrobatidis* survived (Table 3). These results suggest that the immunization protocol that generates effective antibody responses in *X. laevis* is not effective in protection of a susceptible species from a normal (epidermal) route of infection.

8. FUTURE DIRECTIONS FOR RESEARCH

8.1. Alternative immunization strategies

Although our immunization protocol appears to be adequate for induction of antibodies to *B. dendrobatidis*, the antibodies were not protective against this pathogen in *B. boreas*. As is the case for mammalian species, development of effective antibody responses to complex cellular antigens or large proteins in *Xenopus* requires T cell help (138,160, 179-181). Therefore, because we showed strong antibody responses, we conclude that our immunization protocol resulted in the activation of T cells and production of cytokines necessary for antibody production. However, protective immunity to fungal pathogens in mammalian hosts is complex involving mediators of the innate immune system (macrophages, neutrophils, natural killer cells, and $\gamma\delta$ -T cells) and the adaptive immune system (T cells of both CD4⁺ and CD8⁺ phenotype and B cells) (rev in 182,183). Protective T cell responses depend on the predominance of the T-helper cells of type 1 (Th1) pathway which involves production of

Xenopus immune defenses against *B. Dendrobatidis*

interferon- γ , interleukin-12, and interleukin-18. These cytokines stimulate production of activated macrophages, cytotoxic T cells, and opsonizing antibodies (183). Although antibodies are raised to fungal pathogens in mammalian systems, there is limited evidence that they are protective (183). Therefore, we believe that it is essential to develop methods to induce more effective T-cell mediated immunity in our model system. Additional studies will test the effectiveness of use of adjuvants to induce more effective T cell-mediated immunity.

8.2. Focus on the skin

Although we have successfully induced a systemic immune response resulting in development of high-titer antibodies against *B. dendrobatidis* in *X. laevis*, chytridiomycosis is an infection that remains confined to the skin. Therefore, it is likely that a successful immunization strategy must be targeted to antigen presenting cells and immune effectors that home to the skin. Studies to introduce *B. dendrobatidis* antigens directly into the skin compartment with adjuvants are planned.

9. PERSPECTIVE AND CONCLUDING REMARKS

Xenopus laevis and *Bufo boreas* have been invaluable as models to study immune defenses against *B. dendrobatidis*. Our current view is that both innate skin defenses and adaptive immune responses are required for control and elimination of this pathogen. *X. laevis* appears to have very effective antimicrobial peptide defenses in the skin, and immunized animals can develop an immune response. In contrast, *B. boreas* has less effective antimicrobial peptide defenses and may succumb if infected with a sufficient number of zoospores prior to development of an effective adaptive immune response. Protection of vulnerable species such as *B. boreas* may depend on our capacity to develop an effective immunization (vaccine) or exposure strategy that allows for adult breeders to become immune in captivity so that they may be released to enable populations to persist until the pathogen declines.

10. ACKNOWLEDGEMENTS

This research was supported by: NSF Integrated Research Challenges in Environmental Biology grants IBN-9977063 and DEB-0213851 (J. Collins, P.I., subcontracts to L.R-S and C.C.), IBN-0131184, IBN-0520847, and IOB-0619536 (to L. R-S), and grants from the Colorado Division of Wildlife (to C. C. and L. L.). We thank the John W. Mumma Native Aquatic Species Restoration Facility of the Colorado Division of Wildlife for providing the *B. dendrobatidis*-free *B. boreas*. We also thank Joyce E. Longcore for providing isolates of *B. dendrobatidis* for use in these studies. Heidi Bustamante and Cassia Rye assisted with the boreal toad infection studies.

11. REFERENCES

1. R. Carson, Silent Spring. Boston: Houghton Mifflin, (1962). P. S. Corn and J. C. Fogelman: on of

montane populations of the northern leopard frog (*Rana pipiens*) in Colorado. *J Herpetol* 18,147-152 (1984)

3. D. F. Bradford: Mass mortality and extinction in a high-elevation population of *Rana mucosa*. *J Herpetol* 25, 174-177 (1991)

4. D. B. Wake: Declining amphibian populations. *Science* 253, 860 (1991)

5. C. Carey: Hypothesis concerning the causes of the disappearance of boreal toads from the mountains of Colorado. *Conserv Biol* 7, 355-362 (1993)

6. C. K. Sherman and M.L. Morton: Population declines of Yosemite toads in the eastern Sierra Nevada of California. *J Herpetol* 27,186-198 (1993)

7. D. F. Bradford, D. M. Graber, and F. Tabatabai: Population declines of the native frog, *Rana muscosa*, in Sequoia and Kings Canyon National Parks, California. *Southwestern Nat* 39, 323-327 (1994)

8. C. A. Drost and G. M. Fellers: Collapse of regional frog fauna in the Yosemite area of the California Sierra Nevada. *Conserv Biol* 10, 414-425 (1996)

9. S. N. Stuart, J. S. Chanson, N. A. Cox, B. E. Young, A. S. L. Rodrigues, D. L. Fischman, and R. W. Waller: Status and trends of amphibian declines and extinctions worldwide. *Science* 306, 1783-1786 (2004).

10. R. A. Alford and S. J. Richards: Global amphibian declines: A problem in applied ecology. *Annu Rev Ecol Syst* 30, 133-65 (1999)

11. J. E. Houlahan, C. S. Findlay, B. R. Schmidt, A. H. Meyer, and S.L. Kuzmin: Quantitative evidence for global amphibian population declines. *Nature* 404, 752-755 (2000)

12. S. J. Hecnar and R. T. M'Closkey: Regional dynamics and the status of amphibians. *Ecology* 77, 2091-2097 (1996)

13. S. J. Hecnar and R. T. M'Closkey: Species richness pattern of amphibians in southwestern Ontario ponds. *J Biogeogr* 25, 763-772 (1998)

14. J. P. Collins and A. Storfer: Global amphibian declines: Sorting the hypotheses. *Divers Distrib* 9, 89-98 (2003)

15. J. A. Pounds and M. L. Crump: Amphibian declines and climate disturbance: The case of the golden toad and the harlequin frog. *Conserv Biol* 8, 72-85 (1994)

16. M. A. Donnelly and M. L. Crump: Potential effects of climate change on two neotropical amphibian assemblages. *Clim Change* 39, 541-561 (1998)

Xenopus immune defenses against *B. Dendrobatidis*

17. J. A. Pounds, M. P. L. Fogden, and J. H. Campbell: Biological response to climate change on a tropical mountain. *Nature* 398, 611-615 (1999)
18. C. Carey and M.A. Alexander: Climate change and amphibian declines: Is there a link? *Divers Distrib* 9, 111-121 (2003)
19. J. A. Pounds, M. R. Bustamante, L. A. Coloma, J. A. Consuegra, M. P. L. Fogden, P. N. Foster, E. La Marca, K. L. Masters, A. Merino-Viteri, R. Puschendorf, S. R. Ron, G. A. Sánchez-Azofeifa, C. J. Still and B. E. Young: Widespread amphibian extinctions from epidemic disease driven by global warming. *Nature* 439, 161-167 (2006)
20. J. M. Kiesecker and A. R. Blaustein: Synergism between UV-B radiation and a pathogen magnifies amphibian embryo mortality in nature. *Proc Natl Acad Sci USA* 92, 11049-11052 (1995)
21. R. Blaustein, J. M. Kiesecker, D. P. Chivers, and R. G. Anthony: Ambient UV-B radiation causes deformities in amphibian embryos. *Proc Natl Acad Sci USA* 94, 13735-13737 (1997)
22. J. M. Kiesecker, A. R. Blaustein, and L. K. Belden: Complex causes of amphibian population declines. *Nature* 410, 681-684 (2001)
23. E. M. Middleton, J. R. Herman, E. A. Celarier, J. W. Wilkinson, C. Carey, and R. J. Rusin: Evaluating ultraviolet radiation exposures with satellite data at sites of amphibian declines in Central and South America. *Conserv Biol* 15, 914-929 (2001)
24. A.R. Blaustein and L. K. Belden: Amphibian defenses against ultraviolet-B radiation. *Evol Dev* 5, 89-97 (2003)
25. D. F. Bradford: Allotopic distribution of native frogs and introduced fishes in high Sierra Nevada lakes of California: Implication of the negative effect of fish introductions. *Copeia* 1989, 775-778 (1989)
26. D. F. Bradford, F. Tabatabai, and D. M. Graber: Isolation of remaining populations of the native frog, *Rana muscosa*, by introduced fishes in Sequoia and Kings Canyon National Parks, California. *Conserv Biol* 7, 882-888 (1993)
27. S. P. Lawler, D. Dritz, T. Strange, and M. Holyoak: Effects of introduced mosquitofish and bullfrogs on the threatened California red-legged frog. *Conserv Biol* 13, 613-622 (1999)
28. V.T. Vredenburg: Reversing introduced species effects: Experimental removal of introduced fish leads to rapid recovery of a declining frog. *Proc Natl Acad Sci USA* 101, 7646-7650 (2004)
29. R. A. Knapp, D. M. Boiano, and V. T. Vredenburg: Removal of nonnative fish results in population expansion of a declining amphibian (mountain yellow-legged frog, *Rana muscosa*). *Biol Conserv* 135, 11-20 (2007)
30. D. W. Sparling, G. M. Fellers, and L. L. McConnell: Pesticides and amphibian population declines in California, USA. *Environ Toxicol Chem* 20, 1591-1595 (2001)
31. C. Davidson, H. B. Shaffer, and M. R. Jennings: Spatial tests of the pesticide drift, habitat destruction, UV-B, and climate-change hypotheses for California amphibian declines. *Conserv Biol* 16, 1588-1601 (2002)
32. R. Blaustein, J. M. Romanic, J. M. Kiesecker, and A. C. Hatch: Ultraviolet radiation, toxic chemicals and amphibian population declines. *Divers Distrib* 9, 123-140. (2003)
33. L. Berger, R. Speare, P. Daszak, D. E. Green, A. A. Cunningham, C. L. Goggin, R. Slocombe, M. A. Ragan, A. D. Hyatt, K. R. McDonald, H. B. Hines, K. R. Lips, G. Marantelli, and H. Parkes: Chytridiomycosis causes amphibian mortality associated with population declines in the rain forests of Australia and Central America. *Proc Natl Acad Sci USA* 95, 9031-9036 (1998)
34. J. E. Longcore, A. P. Pessier, and D. K. Nichols: *Batrachochytrium dendrobatidis* gen. et sp. nov., a chytrid pathogenic to amphibians. *Mycologia* 91, 219-227 (1999)
35. P. Pessier, D. K. Nichols, J. E. Longcore, and M. S. Fuller: Cutaneous chytridiomycosis in poison dart frogs (*Dendrobates* spp.) and White's tree frogs (*Litoria caerulea*). *J Vet Diagn Invest* 11, 194-199 (1999)
36. L. J. Rachowicz, R. A. Knapp, J. A. Morgan, M. J. Stice, V. T. Vredenburg, J. M. Parker, and C. J. Briggs: Emerging infectious disease as a proximate cause of amphibian mass mortality. *Ecology* 87, 1671-1683 (2006)
37. C. Carey, J. E. Bruzgul, L. J. Livo, M. L. Walling, K. A. Kuehl, B. F. Dixon, A. P. Pessier, R. A. Alford, and K. B. Rogers: Experimental exposures of boreal toads (*Bufo boreas*) to a pathogenic chytrid fungus (*Batrachochytrium dendrobatidis*). *EcoHealth* 3, 5-21 (2006)
38. K. R. Lips, F. Brem, R. Brenes, J. D. Reeve, R. A. Alford, J. Voyles, C. Carey, L. Livo, A. P. Pessier, and J. P. Collins: Emerging infectious disease and the loss of biodiversity in a Neotropical amphibian community. *Proc Natl Acad Sci USA* 103, 3165-3170 (2006).
39. S. Barrionuevo and S. Mangione: Chytridiomycosis in two species of *Telmatobius* (Anura: *Leptodactylidae*) from Argentina. *Dis Aquat Organ* 73, 171-174 (2006)
40. R. Speare and L. Berger: Global distribution of chytridiomycosis in amphibians. World Wide Web - <http://www.jcu.edu.au/school/phtm/PHTM/frogs/chyglb.htm>. (2007)

Xenopus immune defenses against *B. Dendrobatidis*

41. C. Carey, N. Cohen, and L. Rollins-Smith: Amphibian declines: An immunological perspective. *Dev Comp Immunol* 23, 459-472 (1999)
42. P. Daszak, L. Berger, A. A. Cunningham, A. D. Hyatt, D. E. Green, and R. Speare: Emerging infectious diseases and amphibian population declines. *Emerg Infect Dis* 5, 735-748 (1999)
43. P. Daszak, A. A. Cunningham, and A. D. Hyatt: Infectious disease and amphibian population declines. *Divers Distrib* 9, 141-150 (2003)
44. L. F. Skerratt, L. Berger, R. Speare, S. Cashins, K. R. McDonald, A. D. Phillott, H. B. Hines, and N. Kenyon: Spread of chytridiomycosis has caused the rapid global decline and extinction of frogs. *EcoHealth* 4, 125-134 (2007)
45. T. Y. James, F. Kauff, C. L. Schoch, P. B. Matheny, V. Hofstetter, C. J. Cox, G. Celio, C. Gueidan, E. Fraker, J. Miadlikowska, H. T. Lumbsch, A. Rauhut, V. Reeb, A. E. Arnold, A. Amtoft, J. E. Stajich, K. Hosaka, G. H. Sung, D. Johnson, B. O'Rourke, M. Crockett, M. Binder, J. M. Curtis, J. C. Slot, Z. Wang, A. W. Wilson, A. Schüssler, J. E. Longcore, K. O'Donnell, S. Mozley-Standridge, D. Porter, P. M. Letcher, M. J. Powell, J. W. Taylor, M. M. White, G. W. Griffith, D. R. Davies, R. A. Humber, J. B. Morton, J. Sugiyama, A. Y. Rossman, J. D. Rogers, D. H. Pfister, D. Hewitt, K. Hansen, S. Hambleton, R. A. Shoemaker, J. Kohlmeyer, B. Volkmann-Kohlmeyer, R. A. Spotts, M. Serdani, P. W. Crous, K. W. Hughes, K. Matsuura, E. Langer, G. Langer, W. A. Untereiner, R. Lücking, B. Büdel, D. M. Geiser, A. Aptroot, P. Diederich, I. Schmitt, M. Schultz, R. Yahr, D. S. Hibbett, F. Lutzoni, D. J. McLaughlin, J. W. Spatafora, and R. Vilgalys: Reconstructing the early evolution of fungi using a six-gene phylogeny. *Nature* 443, 818-822 (2006)
46. T. Y. James, P. M. Letcher, J. E. Longcore, S. E. Mozley-Standridge, D. Porter, M. J. Powell, G. W. Griffith, and R. Vilgalys: A molecular phylogeny of the flagellated fungi (*Chytridiomycota*) and description of a new phylum (*Blastocladiomycota*). *Mycologia* 98, 860-871 (2006)
47. D. S. Hibbett, M. Binder, J. F. Bischoff, M. Blackwell, P. F. Cannon, O. E. Eriksson, S. Huhndorf, T. James, P. M. Kirk, R. Lücking, H. Thorsten Lumbsch, F. Lutzoni, P. B. Matheny, D. J. McLaughlin, M. J. Powell, S. Redhead, C. L. Schoch, J. W. Spatafora, J. A. Stalpers, R. Vilgalys, M. C. Aime, A. Aptroot, R. Bauer, D. Begerow, G. L. Benny, L. A. Castlebury, P. W. Crous, Y-C. Dai, W. Gams, D. M. Geiser, G. W. Griffith, C. Gueidan, D. L. Hawksworth, G. Hestmark, K. Hosaka, R. A. Humber, K. D. Hyde, J. E. Ironside, U. Kõljalg, C. P. Kurtzman, K-H. Larsson, R. Lichtwardt, J. Longcore, J. Miadlikowska, A. Miller, J-M. Moncalvo, S. Mozley-Standridge, F. Oberwinkler, E. Parmasto, V. Reeb, J. D. Rogers, C. Roux, L. Ryvarden, J. P. Sampaio, A. Schüßler, J. Sugiyama, R. G. Thorn, L. Tibell, W. A. Untereiner, C. Walker, Z. Wang, A. Weir, M. Weiss, M. M. White, K. Winka, Y-J. Yao, and N. Zhang: A higher-level phylogenetic classification of fungi. *Mycol Res* 111, 509-547 (2007)
48. L. Berger, A. D. Hyatt, R. Speare, and J. E. Longcore: Life cycle stages of the amphibian chytrid *Batrachochytrium dendrobatidis*. *Dis Aquat Org* 68, 51-63 (2005)
49. J. Voyles, L. Berger, S. Young, R. Speare, R. Webb, J. Warner, D. Rudd, R. Campbell, and L. F. Skerratt: Electrolyte depletion and osmotic imbalance in amphibians with chytridiomycosis. *Dis Aquat Org* 77, 113-118 (2007)
50. C. Weldon, L. H. du Preez, A. D. Hyatt, R. Muller, and R. Speare: Origin of the amphibian chytrid fungus. *Emerg Infect Dis* 10, 2100-2105 (2004)
51. J. M. Parker, I. Mikaelian, N. Hahn, and H. E. Diggs: Clinical diagnosis and treatment of epidermal chytridiomycosis in African clawed frogs, (*Xenopus tropicalis*). *Comp Med* 52, 265-268 (2002)
52. L. A. Rollins-Smith and J. M. Conlon: Antimicrobial peptide defenses against chytridiomycosis, an emerging infectious disease of amphibian populations. *Dev Comp Immunol* 29, 589-598 (2005)
53. E. Muths, P. S. Corn, A. P. Pessier, and D. E. Green: Evidence for disease-related amphibian decline in Colorado. *Biol Conserv* 110, 357-365 (2003)
54. N. Yamaguchi, S. Kurashige, and S. Mitsuhashi: Immune response in *Xenopus laevis* and immunochemical properties of the serum antibodies. *Immunology* 24, 109-118 (1973)
55. D. Grossberger, A. Marcuz, L. Du Pasquier, and J. D. Lambris: Conservation of structural and functional domains in complement component C3 of *Xenopus* and mammals. *Proc Natl Acad Sci USA* 86, 1323-1327 (1989)
56. L. B. Jensen and C. Koch: An assay for complement factor B in species at different levels of evolution. *Dev Comp Immunol* 15, 173-179 (1991)
57. L. M. Kunnath-Muglia, G. H. Chang, R. B. Sim, A. J. Day, and R. A. Ezekowitz: Characterization of *Xenopus laevis* complement factor I structure-conservation of modular structure except for an unusual insert not present in human factor I. *Mol Immunol* 30, 1249-1256 (1993)
58. Y. Kato, L. Salter-Cid, M. F. Flajnik, M. Kasahara, C. Namikawa, M. Sasaki, and M. Nonaka: Isolation of the *Xenopus* complement factor B complementary DNA and linkage of the gene to the frog MHC. *J Immunol* 153, 4546-4554 (1994)
59. Y. Kato, L. Salter-Cid, M. F. Flajnik, C. Namikawa, M. Sasaki, and M. Nonaka: Duplication of the MHC-linked

Xenopus immune defenses against *B. Dendrobatidis*

- Xenopus* complement factor B gene. *Immunogenetics* 42, 196-203 (1995)
60. R. Mo, Y. Kato, M. Nonaka, K. Nakayama, and M. Takahashi: Fourth component of *Xenopus laevis* complement: cDNA cloning and linkage analysis of the frog MHC. *Immunogenetics* 43, 360-369 (1996)
61. Y. Endo, M. Takahashi, M. Nakao, H. Saiga, H. Sekine, M. Matsushita, M. Nonaka, and T. Fujita: Two lineages of mannose-binding lectin-associated serine protease (MASP) in vertebrates. *J Immunol* 161, 4924-4930 (1998)
62. Y. Kakinuma, Y. Endo, M. Takahashi, M. Nakata, M. Matsushita, S. Takenoshita, and T. Fujita: Molecular cloning and characterization of novel ficolins from *Xenopus laevis*. *Immunogenetics* 55, 29-37 (2003)
63. H. Boshra, A. E. Gelman, and J. O. Sunyer: Structural and functional characterization of complement C4 and C1s-like molecules in teleost fish: insights into the evolution of classical and alternative pathways. *J Immunol* 173, 349-359 (2004)
64. M. Nonaka and A. Kimura: Genomic view of the evolution of the complement system. *Immunogenetics* 58, 701-713 (2006)
65. Y. Zhao, Y. Jin, W-H. Lee and Y. Zhang: Purification of a lysozyme from skin secretions of *Bufo andrewsi*. *Comp Biochem Physiol C Toxicol Pharmacol* 142, 46-52 (2006).
66. S. L. Klein, R. L. Strausberg, L. Wagner, J. Pontius, S. W. Clifton, and P. Richardson: Genetic and genomic tools for *Xenopus* research: The NIH *Xenopus* initiative. *Dev Dyn* 225, 384-391 (2002)
67. D. S. Ostrovsky, J. A. Snyder, T. Iwata, K. I. Izaka, D. S. Maglott, and G. W. Nace: Frog lysozyme. I. Its identification, occurrence as isozymes, and quantitative distribution in tissues of the leopard frog, *Rana pipiens*. *J Exp Zool* 195, 279-290 (1976)
68. J. Carillo-Farga, A. Castell, A. Pérez, and A. Rondán: Langerhans-like cells in amphibian epidermis. *J Anat* 172, 39-45 (1990)
69. L. Du Pasquier and M. F. Flajnik: Expression of MHC class II antigens during *Xenopus* development. *Dev Immunol* 1, 85-95 (1990)
70. E. Castell-Rodríguez, A. Hernandez-Peñalosa, E. A. Sampedro-Carrillo, M. A. Herrera-Enriquez, S. J. Alvarez-Pérez, and A. Rondan-Zarate: ATPase and MHC class II molecules co-expression in *Rana pipiens* dendritic cells. *Dev Comp Immunol* 23, 473-485 (1999)
71. L. Mescher, W. L. Wolf, E. A. Moseman, B. Hartman, C. Harrison, E. Nguyen, and A. W. Neff: Cells of cutaneous immunity in *Xenopus*: Studies during larval development and limb regeneration. *Dev Comp Immunol* 31, 383-393 (2007)
72. T. L. Horton, P. Ritchie, M. D. Watson, and J. D. Horton: Natural cytotoxicity towards allogeneic tumor targets in *Xenopus* mediated by diverse splenocyte populations. *Dev Comp Immunol* 22, 217-230 (1998)
73. T. L. Horton, R. Minter, R. Stewart, P. Ritchie, M. D. Watson, and J. D. Horton: *Xenopus* NK Cells identified by novel monoclonal antibodies. *Eur J Immunol* 30, 604-613 (2000)
74. L. Rau, J. Gantress, A. Bell, R. Stewart, T. Horton, N. Cohen, J. Horton, and J. Robert: Identification and characterization of *Xenopus* CD8⁺ T cells expressing an NK cell-associated molecule. *Eur J Immunol* 32, 1574-1583 (2002)
75. T. L. Horton, R. Stewart, N. Cohen, L. Rau, P. Ritchie, M. D. Watson, J. Robert, and J. D. Horton: Ontogeny of *Xenopus* NK cells in the absence of MHC class I antigens. *Dev Comp Immunol* 27, 715-726 (2003)
76. S. R. Krutzik and R. L. Modlin: The role of Toll-like receptors in combating mycobacteria. *Semin Immunol* 16, 35-41 (2004)
77. K. Miyake: Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. *Semin Immunol* 19, 3-10 (2007)
78. T. Kawai and S. Akira: TLR signaling. *Semin Immunol* 19, 24-32 (2007)
79. J. C. Roach, G. Glusman, L. Rowen, A. Kaur, M. K. Purcell, K. D. Smith, L. E. Hood, and A. Aderem: The evolution of vertebrate Toll-like receptors. *Proc Natl Acad Sci USA* 102, 9577-9582 (2005)
80. Ishii, M. Kawasaki, M. Matsumoto, S. Tochinai, and T. Seya: Phylogenetic and expression analysis of amphibian *Xenopus* Toll-like receptors. *Immunogenetics* 59, 281-293 (2007)
81. S. Bellocchio, S. Moretti, K. Perruccio, F. Fallarino, S. Bozza, C. Montagnoli, P. Mosci, G. B. Lipford, L. Pitzurra, and L. Ronani: TLRs govern neutrophil activity in aspergillosis. *J Immunol* 173, 7406-7415 (2004)
82. M. G. Netea, G. D. Brown, B. J. Kullberg, and N. A. R. Gow: An integrated model of the recognition of *Candida albicans* by the innate immune system. *Nat Rev Microbiol* 6, 67-78 (2008)
83. G. A. Noble and E. R. Noble: On the histology of frog skin glands. *Trans Am Microscop Soc* 63, 254-263 (1944)
84. M. Bovbjerg: Development of the glands of the dermal plicae in *Rana pipiens*. *J Morph* 113, 231-243 (1963)

Xenopus* immune defenses against *B. Dendrobatidis

85. E. Sjöberg and Å. Flock: Innervation of skin glands in the frog. *Cell Tiss Res* 172, 81-91 (1976)
86. J. W. Mills and B. E. Prum: Morphology of the exocrine glands of the frog skin. *Am J Anat* 171, 91-106 (1984)
87. W. E. Duellman and L. Trueb, *Biology of Amphibians*. New York: McGraw Hill. pp. 369-370 (1986)
88. U. Schumacher, E. Adam, F. Hauser, J. C. Probst, and W. Hoffmann: Molecular anatomy of a skin gland: Histochemical and biochemical investigations on the mucous glands of *Xenopus laevis*. *J Histochem Cytochem* 42, 57-65 (1994)
89. L. Goniakowska-Witalińska and U. Kubiczek: The structure of the skin of the tree frog (*Hyla arborea arborea* L.). *Ann Anat* 180, 237-246 (1998)
90. V. Erspamer: Bioactive secretions of the amphibian integument. In: H. Heatwole, G.T. Barthalmus, and A.Y. Heatwole, eds., *Amphibian Biology*. Volume 1 The Integument. Chipping Norton: Surrey Beatty and Sons (1994).
91. J. W. Daly: The chemistry of poisons in amphibian skin. *Proc Natl Acad Sci* 92, 9-13 (1995)
92. P. Nicolas and A. Mor: Peptides as weapons against microorganisms in the chemical defense system of vertebrates. *Annu Rev Microbiol* 49, 277-304 (1995)
93. M. Simmaco, G. Mignogna, and D. Barra: Antimicrobial peptides from amphibian skin: What do they tell us? *Biopolymers (Peptide Science)* 47, 435-450 (1998)
94. M. Zasloff: Antimicrobial peptides of multicellular organisms. *Nature* 415, 389-395 (2002)
95. C. Rinaldi: Antimicrobial peptides from amphibian skin: An expanding scenario. *Curr Opin Chem Biol* 6, 799-804 (2002)
96. J. M. Conlon, J. Kolodziejek, and N. Nowotny: Antimicrobial peptides from ranid frogs: Taxonomic and phylogenetic markers and a potential source of new therapeutic agents. *Biochim Biophys Acta* 1696, 1-14 (2004)
97. M. A., Apponyi, T. L. Pukala, C. S. Brinkworth, V. M. Vaselli, J. H. Bowie, M. J. Tyler, G. W. Booker, J. C. Wallace, J. A. Carver, F. Separovic, J. Doyle, and L. E. Llewellyn: Host-defence peptides of Australian anurans: Structure, mechanisms of action and evolutionary significance. *Peptides* 25, 1035-1054 (2004)
98. G. J. Dockray and C. R. Hopkins: Caerulein secretion by dermal glands in *Xenopus laevis*. *J Cell Biol* 64, 724-733 (1975)
99. M. G. Giovannini, L. Poulter, B. W. Gibson, and D. H. Williams: Biosynthesis and degradation of peptides derived from *Xenopus laevis* prohormones. *Biochem J* 243, 113-120 (1987)
100. J. Benson and M. E. Hadley: *In vitro* characterization of adrenergic receptors controlling skin gland secretion in two anurans *Rana pipiens* and *Xenopus laevis*. *Comp Biochem Physiol* 30, 857-864 (1969)
101. Holmes and M. Balls: *In vitro* studies on the control of myoepithelial cell contraction in the granular glands of *Xenopus laevis* skin. *Gen Comp Endocrinol* 36, 255-263 (1978)
102. M., Neuwirth, J. W., Daly, C. W. Myers, and L. W. Tice: Morphology of the granular secretory glands in skin of poison-dart frogs (*Dendrobatidae*). *Tissue Cell* 11, 755-771 (1979)
103. R. C. Toledo and C. Jared: Cutaneous granular glands and amphibian venoms. *Comp Biochem Physiol* 111A, 1-29 (1995)
104. M. R. Yeaman and N. Y. Yount: Mechanisms of antimicrobial peptide action and resistance. *Pharmacol Rev* 55, 27-55 (2003)
105. Diner and G. J. V. Nossal: Phylogenetic studies on the immune response I. Localization of antigens and immune response in the toad, *Bufo marinus*. *Immunology* 10, 535-542 (1966)
106. Diener, and J. Marchalonis: Cellular and humoral aspects of the primary immune response of the toad, *Bufo marinus*. *Immunology* 18, 279-293 (1970)
107. H. H. Lin, B. E. Caywood, and D. T. Rowlands Jr.: Primary and secondary immune responses of the marine toad (*Bufo marinus*) to bacteriophage f2. *Immunology* 20, 373-380 (1971)
108. N. Kraft and K. Shortman: Differentiation of antibody-forming cells in the toad spleen. A study using density and sedimentation velocity cell separation. *J Cell Biol* 52, 438-452 (1972)
109. J. D. Horton and M. J. Manning: Response to skin allografts in *Xenopus laevis* following thymectomy at early stages of lymphoid organ maturation. *Transplantation* 14, 141-154 (1972)
110. S. Tochikai and C. Katagiri: Complete abrogation of immune response to skin allografts and rabbit erythrocytes in the early thymectomized *Xenopus*. *Develop Growth and Diff* 17, 383-394 (1975)
111. J. J. Rimmer and J. D. Horton: Allograft rejection in larval and adult *Xenopus* following early thymectomy. *Transplantation* 23, 142-148 (1977)
112. L. Du Pasquier and J. D. Horton: The effect of thymectomy on the mixed leukocyte reaction and

Xenopus* immune defenses against *B. Dendrobatidis

phytohemagglutinin responsiveness in the clawed toad *Xenopus laevis*. *Immunogenetics* 3, 105-112 (1976)

113. N. Green and N. Cohen: Phylogeny of immunocompetent cells: III. Mitogen response characteristics of lymphocyte subpopulations from normal and thymectomized frogs (*Xenopus laevis*). *Cell Immunol* 48, 59-70 (1979)

114. Hadji-Azimi, V. Coosemans, and C. Canicatti: Atlas of adult *Xenopus laevis laevis* hematology. *Dev Comp Immunol* 11, 807-874 (1987)

115. M. J. Manning and J. D. Horton: RES structure and function of the amphibia. In: N. Cohen and M. M. Siegel, eds., *The Reticuloendothelial System A Comprehensive Treatise 3. Phylogeny and Ontogeny*. New York. Plenum Press (1982)

116. M. F. Flajnik and L. Du Pasquier: The major histocompatibility complex of frogs. *Immunol Rev* 113, 47-63 (1990)

117. M. F. Flajnik, Y. Ohta, C. Namikawa-Yamada, M. Nonaka: Insight into the primordial MHC from studies of ectothermic vertebrates. *Immunol Rev* 167, 59-67 (1999)

118. M. F. Flajnik and M. Kasahara: Comparative genomics of the MHC: Glimpses into the evolution of the adaptive immune system. *Immunity* 15, 351-362 (2001)

119. B. P. Shum, D. Avila, L. Du Pasquier, M. Kasahara, and M. F. Flajnik: Isolation of a classical class I cDNA from an amphibian: Evidence for only one locus in the *Xenopus* MHC. *J Immunol* 151, 5376-5386 (1993)

120. C. Namikawa, L. Salter-Cid, M. F. Flajnik, Y. Kato, M. Nonaka, and M. Sasaki: Isolation of *Xenopus* LMP-7 homologues: Striking allelic diversity and linkage to the MHC. *J Immunol* 155, 1964-1971 (1995)

121. M. Nonaka, C. Namikawa-Yamada, M. Sasaki, L. Salter-Cid, and M. F. Flajnik: Evolution of proteasome subunits δ and LMP2: Complementary cDNA cloning and linkage analysis with MHC in lower vertebrates. *J Immunol* 159, 734-740 (1997)

122. Y. Ohta, S. J. Powis, R. L. Lohr, M. Nonaka, L. Du Pasquier and M. F. Flajnik: Two highly divergent ancient allelic lineages of the transporter associated with antigen processing (*TAP*) gene in *Xenopus*: Further evidence for co-evolution among MHC class I region genes. *Eur J Immunol* 33, 3017-3027 (2003)

123. Y. Ohta, S. J. Powis, W. J. Coadwell, D. E. Haliniewski, Y. Liu, H. Li, and M. F. Flajnik: Identification and genetic mapping of *Xenopus TAP2* genes. *Immunogenetics* 49, 171-182 (1999)

124. K. Sato, M. F. Flajnik, L. Du Pasquier, M. Katagiri, and M. Kasahara: Evolution of the MHC:

Isolation of class II β -chain cDNA clones from the amphibian *Xenopus laevis*. *J Immunol* 150, 2831-2843 (1993)

125. Y. Liu, M. Kasahara, L. L. Rumpf, and M. F. Flajnik: *Xenopus* class II A genes: Studies of genetics, polymorphism, and expression. *Dev Comp Immunol* 26, 735-750 (2002)

126. T. Nakamura, A. Sekizawa, T. Fujii, and C. Katagiri: Cosegregation of polymorphic C4 with the MHC in the frog, *Xenopus laevis*. *Immunogenetics* 23, 181-186 (1986)

127. L. Salter-Cid, M. Kasahara, and M. F. Flajnik: *Hsp70* genes are linked to the *Xenopus* major histocompatibility complex. *Immunogenetics* 39, 1-7 (1994)

128. Y. Ohta, W. Goetz, M. Z. Hossain, M. Nonaka, and M. F. Flajnik: Ancestral organization of the MHC revealed in the amphibian *Xenopus*. *J Immunol* 176, 3674-3685 (2006)

129. L. Du Pasquier, J. Robert, M. Courtet, and R. Mussmann: B-cell development in the amphibian *Xenopus*. *Immunol Rev* 175, 201-213 (2000)

130. Hadji-Azimi and M. Michea-Hamzehpour: *Xenopus laevis* 19S immunoglobulin. Ultrastructure and J Chain isolation. *Immunology* 30, 587-591 (1976)

131. J. Schwager, D. Grossberger, and L. Du Pasquier: Organization and rearrangement of immunoglobulin M genes in the amphibian *Xenopus*. *EMBO J* 7, 2409-2415 (1988)

132. J. Schwager, C. A. Mikoryak, and L. A. Steiner: Amino acid sequence of heavy chain from *Xenopus laevis* IgM deduced from cDNA sequence: Implications for evolution of immunoglobulin domains. *Proc Natl Acad Sci USA* 85, 2245-2249 (1988)

133. C. T. Amemiya, R. N. Haire, and G. W. Litman: Nucleotide sequence of a cDNA encoding a third distinct *Xenopus* immunoglobulin heavy chain isotype. *Nucleic Acids Res* 17, 5388 (1989)

134. R. Mussmann, M. Wilson, A. Marcuz, M. Courtet, and L. Du Pasquier: Membrane exon sequences of the three *Xenopus* Ig classes explain the evolutionary origin of mammalian isotypes. *Eur J Immunol* 26, 409-414 (1996)

135. Hsu, M. F. Flajnik, and L. Du Pasquier: A third immunoglobulin class in amphibians. *J Immunol* 135, 1998-2004 (1985)

136. R. Mussmann, L. Du Pasquier, and E. Hsu: Is *Xenopus* IgX an analog of IgA? *Eur J Immunol* 26, 2823-2830 (1996)

137. E. Hsu and L. Du Pasquier: Ontogeny of the immune system in *Xenopus* I. Larval immune response. *Differentiation* 28, 109-115 (1984)

Xenopus immune defenses against *B. Dendrobatidis*

138. R. J. Turner and M. J. Manning: Thymic dependence of amphibian antibody responses. *Eur J Immunol* 4, 343-346 (1974)
139. R. Mussmann, M. Courtet, J. Schwager, and L. Du Pasquier: Microsites for immunoglobulin switch recombination breakpoints from *Xenopus* to mammals. *Eur J Immunol* 27, 2610-2619 (1997)
140. Y. Ohta and M. Flajnik: IgD, like IgM, is a primordial immunoglobulin class perpetuated in most jawed vertebrates. *Proc Natl Acad Sci USA* 103, 10723-10728 (2006)
141. D. Watkins, S. C. Parsons, and N. Cohen: A factor with interleukin-1-like activity is produced by peritoneal cells from the frog, *Xenopus laevis*. *Immunology* 62, 669-673 (1987)
142. J. Zou, S. Bird, R. Minter, J. Horton, C. Cunningham, and C. J. Secombes: Molecular cloning of the gene for interleukin-1 β from *Xenopus laevis* and analysis of expression *in vivo* and *in vitro*. *Immunogenetics* 51, 332-338 (2000)
143. D. Watkins and N. Cohen: Mitogen-activated *Xenopus laevis* lymphocytes produce a T-cell growth factor. *Immunology* 62, 119-125 (1987)
144. L. Haynes and N. Cohen: Further characterization of an interleukin-2-like cytokine produced by *Xenopus laevis* T lymphocytes. *Dev Immunol* 3, 231-238 (1993)
145. L. Haynes and N. Cohen: Transforming growth factor beta (TGF beta) is produced by and influences the proliferative response of *Xenopus laevis* lymphocytes *Dev Immunol* 3, 223-230 (1993)
146. J. Zou, C. Tafalla, J. Truckle, and C. J. Secombes: Identification of a second group of type I IFNs in fish sheds light on IFN evolution in vertebrates. *J Immunol* 179, 3859-3871 (2007)
147. M. Braun, M. Wunderlin, K. Spieth, W. Knochel, P. Gierschik, and B. Moepps: *Xenopus laevis* stromal cell-derived factor 1: Conservation of structure and function during vertebrate development. *J Immunol* 168, 2340-2347 (2002)
148. K. J. Laing and C. J. Secombes: Chemokines. *Dev Comp Immunol* 28, 443-460 (2004)
149. X. Chardonens and L. Du Pasquier: Induction of skin allograft tolerance during metamorphosis of the toad *Xenopus laevis*: A possible model for studying generation of self tolerance to histocompatibility antigens. *Eur J Immunol* 3, 569-573 (1973)
150. L. Du Pasquier, X. Chardonens, and V. C. Miggiano: A major histocompatibility complex in the toad *Xenopus laevis* (Daudin). *Immunogenetics* 1, 482-494 (1975)
151. L. Du Pasquier and X. Chardonens: Genetic aspects of the tolerance to allografts induced at metamorphosis in the toad *Xenopus laevis*. *Immunogenetics* 2, 431-440 (1975)
152. S. J. DiMarzo and N. Cohen: An *in vivo* study of the ontogeny of alloreactivity in the frog, *Xenopus laevis*. *Immunology* 45, 39-48 (1982)
153. S. J. DiMarzo and N. Cohen: Immunogenetic aspects of *in vivo* allotolerance induction during the ontogeny of *Xenopus laevis*. *Immunogenetics* 16, 103-116 (1982)
154. E. H. Barlow and N. Cohen: The thymus dependency of transplantation allotolerance in the metamorphosing frog *Xenopus laevis*. *Transplantation* 35, 612-619 (1983).
155. N. Obara, H. Kawahara, and C. Katagiri: Response to skin grafts exchanged among siblings of larval and adult gynogenetic diploids in *Xenopus laevis*. *Transplantation* 36, 91-95 (1983)
156. N. Cohen, S. DiMarzo, L. Rollins-Smith, E. Barlow, and S. Vanderschmidt-Parsons: The ontogeny of allo-tolerance and self-tolerance in larval *Xenopus laevis*. In M. Balls and M. Bownes, eds., *Metamorphosis*. Oxford UK: Oxford University Press (1985)
157. R. Kobel and L. Du Pasquier: Production of large clones of histocompatible, fully identical clawed toads (*Xenopus*). *Immunogenetics* 2, 87-91 (1975)
158. B. Blomberg, C. C. A. Bernard, and L. Du Pasquier: *In vitro* evidence for T-B lymphocyte collaboration in the clawed toad, *Xenopus*. *Eur J Immunol* 10, 869-876 (1980)
159. M. F. Flajnik, L. Du Pasquier, and N. Cohen: Immune responses of thymus/lymphocyte embryonic chimeras. Studies on tolerance and major histocompatibility complex restriction in *Xenopus*. *Eur J Immunol* 15, 540-547 (1985)
160. F. A. Harding, M. F. Flajnik, and N. Cohen: MHC restriction of T-cell proliferative responses in *Xenopus*. *Dev Comp Immunol* 17, 425-437 (1993)
161. J. Robert, J. Gantress, L. Rau, A. Bell, and N. Cohen: Minor histocompatibility antigen-specific MHC-restricted CD8 T cell responses elicited by heat shock proteins. *J Immunol* 168, 1697-1703 (2002)
162. M. F. Flajnik, E. Taylor, C. Canel, D. Grossberger, and L. Du Pasquier: Reagents specific for MHC I antigens of *Xenopus*. *Am Zool* 31, 580- 591 (1991)
163. J. Robert, H. Morales, W. Buck, N. Cohen, S. Marr, and J. Gantress: Adaptive immunity and histopathology in frog virus 3-infected *Xenopus*. *Virology* 332, 667-675 (2005)
164. D. Morales and J. Robert: Characterization of primary and memory CD8 T-cell responses against

Xenopus* immune defenses against *B. Dendrobatidis

ranavirus (FV3) in *Xenopus laevis*. *J Virol* 81, 2240-2248 (2007)

165. P. Rast, R. N. Haire, R. T. Litman, S. Pross, and G. W. Litman: Identification and characterization of T-cell antigen receptor-related genes in phylogenetically diverse vertebrate species. *Immunogenetics* 42, 204-212 (1995)

166. Chretien, A. Marcuz, J. Fellah, J. Charlemagne, and L. Du Pasquier: The T cell receptor beta genes of *Xenopus*. *Eur J Immunol* 27,763-771 (1997)

167. R. N. Haire, M. K. Kitzen Hainfeld, J. B. Turpen, and G. W. Litman: Structure and diversity of T-lymphocyte antigen receptors alpha and gamma in *Xenopus*. *Immunogenetics* 54, 431-438 (2002)

168. M. Zasloff: Magainins, a class of antimicrobial peptides from *Xenopus laevis* skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor. *Proc Natl Acad Sci USA* 84, 5449-5453 (1987)

169. D. Andreu, H. Aschauer, G. Kreil, and R. B. Merrifield: Solid-phase synthesis of PYLa and isolation of its natural counterpart PGLa (PYLa- (4-24)) from skin secretion of *Xenopus laevis*. *Eur J Biochem* 149, 531-535 (1985)

170. S. James, B. F. Gibbs, K. Toney, and H. P. J. Bennett: Purification of antimicrobial peptides from an extract of the skin of *Xenopus laevis* using heparin-affinity HPLC: Characterization by ion-spray mass spectrometry. *Anal Biochem* 217, 84-90 (1994)

171. Sures and M. Crippa: Xenopsin: The neurotensin-like octapeptide from *Xenopus* skin at the carboxyl terminus of its precursor. *Proc Natl Acad Sci USA* 81, 380-384 (1984)

172. S. Moore, C. L. Bevins, M. M. Brasseur, N. Tomassini, K. Turner, H. Eck, and M. Zasloff: Antimicrobial peptides in the stomach of *Xenopus laevis*. *J Biol Chem* 266, 19851-19857 (1991)

173. Richter, R. Egger, and G. Kreil: Sequence of preprocaerulein cDNAs cloned from skin of *Xenopus laevis*. A small family of precursors containing one, three, or four copies of the final product. *J Biol Chem* 261, 3676-3680 (1986)

174. D. C. Woodhams, J. Voyles, K. R. Lips, C. Carey, and L. A. Rollins-Smith: Predicted disease susceptibility in a Panamanian amphibian assemblage based on skin peptide defenses. *J Wildl Dis* 42, 207-218 (2006)

175. L. A. Rollins-Smith, J. K. Doersam, J. E. Longcore, S. K. Taylor, J. C. Shamblin, C. Carey, and M. A. Zasloff: Antimicrobial peptide defenses against pathogens associated with global amphibian declines. *Dev Comp Immunol* 26, 63-72 (2002)

176. H. V. Westerhoff, M. Zasloff, J. L. Rosner, R. W. Hendler, A. De Waal, A. Vaz Gomes, P. M. Jongsma, A. Riethorst, and D. Juretić: Functional synergism of the

magainins PGLa and magainin-2 in *Escherichia coli*, tumor cells and liposomes. *Eur J Biochem* 228, 257-264 (1995)

177. L. A. Rollins-Smith, L. K. Reinert, C. J. O'Leary, L. E. Houston, and D. C. Woodhams: Antimicrobial peptide defenses in amphibian skin. *Integr Comp Biol* 45, 137-142 (2005)

178. L. McClanahan Jr. and R. Baldwin: Rate of water uptake through the integument of the desert toad, *Bufo punctatus*. *Comp Biochem Physiol* 28, 381-389 (1969)

179. J. D. Horton and M. J. Manning: Effect of early thymectomy on the cellular changes occurring in the spleen of the clawed toad following administration of soluble antigen. *Immunology* 26, 797-807 (1974)

180. J. D. Horton, J. J. Rimmer, and T. L. Horton: The effect of thymectomy at different states of larval development on the immune response of the clawed toad to sheep erythrocytes. *J Exp Zool* 196, 243-249 (1976)

181. C. C. Bernard, G. Bordmann, B. Blomberg, and L. Du Pasquier: Genetic control of T helper cell function in the clawed toad *Xenopus laevis*. *Eur J Immunol* 11,151-155 (1981)

182. J. M. Dan and S. M. Levitz: Prospects for development of vaccines against fungal diseases. *Drug Resist Updat* 9,105-110 (2006)

183. C. Antachopoulos, T. J. Walsh, and E. Roilides. Fungal infections in primary immunodeficiencies. *Eur J Pediatr* 166, 1099-1117 (2007)

Key Words: Immunology, Immune, Infectious Disease of Wildlife, *Xenopus laevis*, *Bufo boreas*, Amphibian, Chytridiomycosis, Chytrid, Innate Immunity, Adaptive Immunity, Review

Send correspondence to: Louise A. Rollins-Smith, Dept. of Microbiology and Immunology, A-5301 Medical Center North, Vanderbilt University Medical Center, Nashville, TN 37232 USA. Tel: 615-343-4119, Fax: 615-343-8648, E-mail: louise.rollins-smith@vanderbilt.edu

<http://www.bioscience.org/current/volS1.htm>